EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quality of Life of Lung Cancer Patients with Immune-Related Endocrinopathies During Immunotherapy: A Prospective Study Based on the EORTC QLQ-C30 and QLQ-LC13 Questionnaires in Romania

Simona Coniac, Mariana Cristina Costache-Outas, Ionuţ-Lucian Antone-Iordache iD, Alexandra-Valentina Anghel, Maria-Alexandra Bobolocu, Andreea Zamfir, Horia-Dan Liscu iD, Andreea-Iuliana Ionescu iD, Corin Badiu iD

Current Oncology · 2025

DOI: 10.3390/curroncol32060332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Simona Coniac und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospice Hope Bucharest, 023642 Bucharest, Romania. Hauptthemen laut MEDLINE: Lung Neoplasms, Quality of Life, Immunotherapy, Endocrine System Diseases. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Globally, lung cancer is the leading cause of cancer death, but immunotherapy has impressively improved the outcomes, generating longer progression-free survival and overall survival. Endocrine immune-related adverse events (irAEs) are mostly irreversible and need life-long hormonal substitution therapy. The evaluation of the quality of life of lung cancer patients experiencing endocrine toxicities during immune checkpoint inhibitor (ICI) treatment is relevant for both patients and healthcare providers. (2)

Methods

This was a prospective cohort study of lung cancer patients treated with immune checkpoint inhibitors in a tertiary-level hospital in Romania from 1 December 2021 to 30 September 2024. Quality of life was assessed using versions of the EORTC QLQ-C30 and EORTC QLQ-LC-13 validated and translated into the Romanian language. We investigated several clinical variables to evaluate their impact on QoL. (3)

Results

Fifty-nine lung cancer patients were evaluated for their QoL before ICI initiation and at the end of the study. Endocrine-irAEs occurred in 17 lung cancer patients (28.8%). Quality of life as assessed using the EORTC questionnaires was statistically significantly improved, even in patients experiencing endocrine-irAEs. (4)

Conclusions

Our prospective cohort study succeeded in delivering the proof of concept of an increased QoL in lung cancer patients who had developed endocrine-irAEs under immunotherapy. Despite toxicities, especially rather frequent endocrine-irAEs, ICIs enabled durable disease control and symptom relief, improving the QoL of the overall trial population. As more lung cancer patients undergo immunotherapy in metastatic or early stages, we draw attention to this particular patient population with autoimmune endocrinopathies, as they will live longer and require life-long hormonal therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsQuality of LifeImmunotherapyEndocrine System DiseasesImmune Checkpoint InhibitorsHumansRomaniaProspective StudiesMaleFemaleMiddle AgedAgedSurveys and Questionnaires

Stichwörter der Autor:innen

Romaniaendocrine immune-related adverse eventsimmune checkpoint inhibitorslung cancerquality of life questionnaire

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Hospice Hope Bucharest, 023642 Bucharest, Romania.
  • Department of Endocrinology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Endocrinology, Coltea Clinical Hospital, 030167 Bucharest, Romania.
  • Department of Radiotherapy, Coltea Clinical Hospital, 030167 Bucharest, Romania.
  • Discipline of Oncological Radiotherapy and Medical Imaging, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Medical Oncology, Colțea Clinical Hospital, 030167 Bucharest, Romania.

ORCID-Profile: Ionuţ-Lucian Antone-Iordache, Horia-Dan Liscu, Andreea-Iuliana Ionescu, Corin Badiu

Zitieren

APA

Coniac, S., Costache-Outas, M. C., Antone-Iordache, I. L., Anghel, A. V., Bobolocu, M. A., Zamfir, A., Liscu, H. D., Ionescu, A. I., & Badiu, C. (2025). Quality of Life of Lung Cancer Patients with Immune-Related Endocrinopathies During Immunotherapy: A Prospective Study Based on the EORTC QLQ-C30 and QLQ-LC13 Questionnaires in Romania. Current Oncology. https://doi.org/10.3390/curroncol32060332

Vancouver

Coniac S, Costache-Outas MC, Antone-Iordache IL, Anghel AV, Bobolocu MA, Zamfir A, et al. Quality of Life of Lung Cancer Patients with Immune-Related Endocrinopathies During Immunotherapy: A Prospective Study Based on the EORTC QLQ-C30 and QLQ-LC13 Questionnaires in Romania. Current Oncology. 2025. doi:10.3390/curroncol32060332

BibTeX
@article{Coniac2025,
  author = {Coniac, Simona and Costache-Outas, Mariana Cristina and Antone-Iordache, Ionuţ-Lucian and Anghel, Alexandra-Valentina and Bobolocu, Maria-Alexandra and Zamfir, Andreea and Liscu, Horia-Dan and Ionescu, Andreea-Iuliana and Badiu, Corin},
  title = {Quality of Life of Lung Cancer Patients with Immune-Related Endocrinopathies During Immunotherapy: A Prospective Study Based on the EORTC QLQ-C30 and QLQ-LC13 Questionnaires in Romania},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32060332}
}
Kostenlos starten →